Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
about
Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the StriatumNew treatments for the motor symptoms of Parkinson's disease.Parkinson's Disease and Its Management: Part 4: Treatment of Motor ComplicationsSystems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.Motor complications in Parkinson's disease.Non-dopaminergic treatments for motor control in Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsWhat are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition.Emerging drugs for levodopa-induced dyskinesia.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management.Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice.
P2860
Q21284508-8ECAEA55-7F4C-4405-A824-30EF7C71A337Q34443682-50A40AFD-7F71-4CD7-9D2E-864C895D6FC9Q36251899-320E9992-0318-49AE-BC85-8FF6A56747ECQ36735012-60096D1B-B7E5-470F-A104-2FFD5BB0D405Q37950426-BF0B1EAB-2779-489A-951B-226A1D93A4A1Q38126817-5A1CE3A4-7724-4B63-B0B8-B215B130B5FEQ38156760-3DE6591A-E01A-4AE5-96AF-091329FA55FFQ38212033-548A7575-0D2C-4022-83C6-2EBED8EEDAF6Q38242091-BF5A951E-7AA2-4D55-8A11-F26D6A5AB8A8Q38262418-3F052349-007F-415B-BBF1-9613B14D8C10Q38284574-D12C8A05-935F-4C1A-BC9B-30B96C9E64CAQ38811387-DD9D6B97-050E-4B0C-9402-AAFCE678F9DEQ38845546-D9452D52-F282-4D24-AC39-05B82FFF6DE3Q39324877-DBCE5464-7BF1-4E80-8694-6200DE1533EEQ41626118-E9BB8930-0DAD-429C-86B8-45F418D8685DQ52147727-3E20DD94-413E-428B-B3F4-2958711D5437
P2860
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
@en
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
@nl
type
label
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
@en
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
@nl
prefLabel
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
@en
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
@nl
P2093
P2860
P921
P356
P1433
P1476
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
@en
P2093
D Peterson
S Konitsiotis
VALID-PD Study Group
P2860
P304
P356
10.1002/MDS.23355
P407
P577
2010-12-13T00:00:00Z